BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38577139)

  • 1. Identification of Genetic Variants in Exon 4 of TP53 in Lung Carcinoma and in Silico Prediction of Their Significance.
    Prasad R; Sharma K; Bhutani K; Prasad S; Manhas S; Kishan J
    Indian J Clin Biochem; 2024 Apr; 39(2):276-282. PubMed ID: 38577139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleotide variations of
    Bukovac A; Kafka A; Hrašćan R; Vladušić T; Pećina-Šlaus N
    Mol Clin Oncol; 2019 Dec; 11(6):563-572. PubMed ID: 31692929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of h-TERT Promoter Mutations in Germline DNA from North Indian Lung Carcinoma Patients.
    Prasad R; Panchal S; Rani I; Kishan J; Parashar G
    Indian J Clin Biochem; 2023 Jan; 38(1):120-127. PubMed ID: 36684496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma.
    Wang Y; Kringen P; Kristensen GB; Holm R; Baekelandt MM; Olivier M; Skomedal H; Hainaut P; Tropé CG; Abeler VM; Nesland JM; Børresen-Dale AL; Helland A
    Hum Mutat; 2004 Jul; 24(1):21-34. PubMed ID: 15221786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 codon 72 polymorphism and type 2 diabetes: a case-control study in South Indian population.
    Punja HK; Nanjappa DP; Babu N; Kalladka K; Shanti Priya Dias B; Chakraborty G; Rao SM; Chakraborty A
    Mol Biol Rep; 2021 Jun; 48(6):5093-5097. PubMed ID: 34181170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
    Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
    Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of XPD and TP53 Gene Polymorphisms on the Risk of Platinum-Based Chemotherapy Induced Toxicity in Bangladeshi Lung Cancer Patients.
    Nairuz T; Bushra YU; Kabir Y
    Asian Pac J Cancer Prev; 2021 Dec; 22(12):3809-3815. PubMed ID: 34967559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development.
    Volodko N; Salla M; Eksteen B; Fedorak RN; Huynh HQ; Baksh S
    World J Gastroenterol; 2015 Sep; 21(36):10358-66. PubMed ID: 26420962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 codon 72 polymorphism and P53 protein expression in colorectal cancer specimens in Isfahan.
    Dastjerdi MN
    Acta Med Iran; 2011; 49(2):71-7. PubMed ID: 21598212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms of the TP53 codon 72 and WRN codon 1367 in individuals from Northern Brazil with gastric adenocarcinoma.
    Khayat AS; Lobo Gatti L; Moura Lima E; de Assumpção PP; Nascimento Motta FJ; Harada ML; Casartelli C; Marques Payão SL; Cardoso Smith MA; Burbano RR
    Clin Exp Med; 2005 Dec; 5(4):161-8. PubMed ID: 16362795
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Cavic M; Spasic J; Krivokuca A; Boljevic I; Kuburovic M; Radosavljevic D; Jankovic R
    J Clin Pathol; 2019 Jan; 72(1):75-80. PubMed ID: 30467244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 codon 72 Gene Polymorphism Paradox in Associated with Various Carcinoma Incidences, Invasiveness and Chemotherapy Responses.
    Lin HY; Huang CH; Wu WJ; Chang LC; Lung FW
    Int J Biomed Sci; 2008 Dec; 4(4):248-54. PubMed ID: 23675098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.
    Popanda O; Edler L; Waas P; Schattenberg T; Butkiewicz D; Muley T; Dienemann H; Risch A; Bartsch H; Schmezer P
    Lung Cancer; 2007 Jan; 55(1):25-34. PubMed ID: 17059853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 (rs1042522, rs28934571) and TP21 (rs1801270, rs1059234) Polymorphisms and Risk of Breast Cancer among Rural Women of Maharashtra: Findings from a Hospital Based Case- Control Study.
    Datkhile KD; Bhosale SJ; Durgawale PP; Jagdale NJ; More AL; Gudur RA; Gudur AK; Patil SR
    Asian Pac J Cancer Prev; 2023 May; 24(5):1611-1619. PubMed ID: 37247280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Functional Significance of TP53 Exon 4-Intron 4 Splice Junction Variants.
    Pinto EM; Maxwell KN; Halalsheh H; Phillips A; Powers J; MacFarland S; Walsh MF; Breen K; Formiga MN; Kriwacki R; Nichols KE; Mostafavi R; Wang J; Clay MR; Rodriguez-Galindo C; Ribeiro RC; Zambetti GP
    Mol Cancer Res; 2022 Feb; 20(2):207-216. PubMed ID: 34675114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients.
    Ignaszak-Szczepaniak M; Horst-Sikorska W; Sawicka J; Kaczmarek M; Slomski R
    Oncol Rep; 2006 Jul; 16(1):65-71. PubMed ID: 16786124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants.
    Deben C; Van den Bossche J; Van Der Steen N; Lardon F; Wouters A; de Beeck KO; Hermans C; Jacobs J; Peeters M; Van Camp G; Rolfo C; Deschoolmeester V; Pauwels P
    Tumour Biol; 2017 Feb; 39(2):1010428317694327. PubMed ID: 28240049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms of the pri-miR-34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer.
    Oh J; Kim JW; Lee BE; Jang MJ; Chong SY; Park PW; Hwang SG; Oh D; Kim NK
    Oncol Rep; 2014 Feb; 31(2):995-1002. PubMed ID: 24337371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
    Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
    Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.